Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/11189
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Coyle, D | - |
dc.contributor.author | Lee, KM | - |
dc.contributor.author | Mamdani, M | - |
dc.contributor.author | Sabarre, KA | - |
dc.contributor.author | Tingley, K | - |
dc.date.accessioned | 2015-07-27T11:03:03Z | - |
dc.date.available | 2015-07-14 | - |
dc.date.available | 2015-07-27T11:03:03Z | - |
dc.date.issued | 2015 | - |
dc.identifier.citation | Headache: The Journal of Head and Face Pain, 55: 236–247, (2015) | en_US |
dc.identifier.issn | 1526-4610 | - |
dc.identifier.uri | http://onlinelibrary.wiley.com/doi/10.1111/head.12585/abstract | - |
dc.identifier.uri | http://bura.brunel.ac.uk/handle/2438/11189 | - |
dc.description.abstract | BACKGROUND: In Ontario, approximately $3.8 billion is spent annually on publicly funded drug programs. The annual growth in Ontario Public Drug Program (OPDP) expenditure has been limited to 1.2% over the course of 3 years. Concurrently, the Ontario Drug Policy Research Network (ODPRN) was appointed to conduct drug class review research relating to formulary modernization within the OPDP. Drug class reviews by ODPRN incorporate a novel methodological technique called reimbursement-based economics, which focuses on reimbursement strategies and may be particularly relevant for policy-makers. OBJECTIVES: To describe the reimbursement-based economics approach. METHODS: Reimbursement-based economics aims to identify the optimal reimbursement strategy for drug classes by incorporating a review of economic literature, comprehensive budget impact analyses, and consideration of cost-effectiveness. This 3-step approach is novel in its focus on the economic impact of alternate reimbursement strategies rather than individual therapies. RESULTS: The methods involved within the reimbursement-based approach are detailed. To facilitate the description, summary methods and findings from a recent application to formulary modernization with respect to the drug class tryptamine-based selective serotonin receptor agonists (triptans) used to treat migraine headaches are presented. CONCLUSIONS: The application of reimbursement-based economics in drug policy reforms allows policy-makers to consider the cost-effectiveness and budget impact of different reimbursement strategies allowing consideration of the trade-off between potential cost savings vs increased access to cost-effective treatments. | en_US |
dc.description.sponsorship | This research was supported by the Ontario Drug Policy Research Network. CC is a recipient of a Vanier Canada Graduate Scholarship through CIHR (Funding reference number – CGV 121171) and a trainee on the CIHR Drug Safety and Effectiveness Network Meta-Analysis team grant (Funding reference number – 116573). | en_US |
dc.language | ENG | - |
dc.language.iso | en | en_US |
dc.publisher | Wiley | en_US |
dc.subject | Cost-effectiveness | en_US |
dc.subject | Drug reimbursement | en_US |
dc.subject | Triptan | en_US |
dc.title | Reimbursement-based economics - What is it and how can we use it to inform drug policy reform? | en_US |
dc.type | Article | en_US |
dc.identifier.doi | http://dx.doi.org/10.1111/head.12585 | - |
dc.relation.isPartOf | Headache | - |
Appears in Collections: | Institute for the Environment |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Fulltext.pdf | 269.52 kB | Adobe PDF | View/Open |
Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.